An open clinical trial of benazepril--a new ACE inhibitor in mild-moderate hypertension.

Abstract

Benazepril hydrochloride, a new non-sulfhydryl ACE inhibitor (ACEI) was studied in a titrated dose of 10 mg-20 mg once a day for 6 weeks in 42 mild to moderate adult hypertensive patients with sitting diastolic blood pressure (SDBP) 95-114 mm Hg. The pre-drug SDBP(mean +/- SE) of 102.5 +/- 0.8 mm Hg showed a significant reduction to 87.5 +/- 0.93 mm Hg at the end of treatment. BP was controlled (SDBP < or = 90 mm Hg) in 34 (81%) patients and a drop of at least 10 mm Hg from the pre-treatment SDBP value was noted in 34 (81%) patients. Common adverse reaction was cough in 8(19%) patients. Clinically significant changes in laboratory evaluations were not seen in any patient. Study showed that benazepril in a dose range of 10 to 20 mg per day is an effective agent for treatment of mild to moderate hypertension.

• Authors: N D Karnik, Y K Oza, S P Sane, R Kaushik, A D Bhatt, K P Chawla, A B Vaidya, V H Yajnik, R C Khokhani
• Journal: The Journal of the Association of Physicians of India (J Assoc Physicians India) Vol. 46 Issue 3 Pg. 283-5 (Mar 1998) ISSN: 0004-5772 [Print] India
• PMID: 11273348 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Benzazepines
• benazepril

Topics

• Adult
• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Benzazepines (therapeutic use)
• Blood Pressure (drug effects)
• Female
• Humans
• Hypertension (drug therapy, physiopathology)
• Male
• Middle Aged